A new blood-based test that combines four protein markers with artificial intelligence has demonstrated potential for early lung cancer detection in a multicenter retrospective study.
Lung cancer screening has increased overall, but significant disparities remain, particularly among rural and underserved populations.
Biofidelity’s test delivers comprehensive genomic profiling for NSCLC patients from tissue or liquid biopsy samples within two days.
NeoGenomics received conditional approval from the New York State Department of Health for its Neo Comprehensive Solid Tumor and NeoTYPE DNA & RNA Lung assays.
Read More
BioAffinity Technologies’ noninvasive lung cancer test is available to Veterans and military personnel for early-stage lung cancer detection.
Read More
A new microchip uses exosome analysis to detect lung cancer from a simple blood draw, enhancing speed and sensitivity in cancer diagnostics.
Read More
The MET Predict assists in identifying NSCLC tumors with MET exon 14 skipping or MET amplification directly from H&E whole slide images.
Read More
Summary: DELFI Diagnostics appointed Thomas Russo as its new CFO to support the company’s...
Read More
A new AI-driven digital pathology platform enables fully automated, rapid, and accurate analysis of lung cancer tissue.
Read More
Several diagnostic associations announced the open comment period for the revised 2018 guideline on molecular testing for lung cancer.
Read More
A new study from OncoHost reveals that its PROphetNSCLC test impacts oncologists’ first-line treatment decisions for metastatic NSCLC.
Read More
Researchers have developed a potential exhaled-breath test for lung diseases by successfully collecting lung biomarkers from human breath.
Read More
Researchers have developed an AI-powered liquid biopsy to identify lung cancer earlier through DNA fragment patterns in blood.
Read More
DELFI’s blood-based Lung test has been clinically validated to enhance early detection of lung cancer, demonstrating high sensitivity.
Read More
OncoHost will highlight the PROphet platform’s capability to predict benefits from therapies across various cancers.
Read More
OSF HealthCare will use DELFI’s FirstLook Lung blood test to enhance lung cancer screening rates and early detection efforts.
Read More
CAP developed recommendations for testing immunotherapy biomarkers, such as PD-L1 and TM), in patients with NSCLC.
Read More
Nucleix will present data that demonstrates the potential of a PCR assay to accurately differentiate between small cell lung cancer subtypes.Â
Read More